Featured Research

from universities, journals, and other organizations

Biologic agents provide relief for children newly diagnosed with Crohn's disease

Date:
February 3, 2014
Source:
American Gastroenterological Association
Summary:
Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF- agents, according to a new study.

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

"While the use of biologic drugs, such as infliximab or adalimumab, is generally reserved for patients who have failed previous therapy for Crohn's disease, little is known about outcomes following the earlier use," said study author Jeffrey S. Hyams, MD, from Connecticut Children's Medical Center, Hartford. "This new research finds that, in children newly diagnosed with moderate to severe Crohn's disease, early anti-TNF-α therapy is more effective at achieving remission than the current standard treatment."

Using data from the RISK Stratification Study, an ongoing, prospective observational research program currently involving 28 pediatric gastroenterology centers in North America, researchers compared the effectiveness of early (within three months after diagnosis) treatment with anti-TNF-α inhibitors, compared with early treatment with immunomodulatory drugs, in attaining clinical remission and facilitating growth in children with Crohn's disease. The current standard of care is corticosteroids followed by the early introduction of immunomodulatory drugs.

At one-year, 85 percent of patients receiving early anti-TNF-α therapy alone were in corticosteroid-free clinical remission, a significantly greater proportion than those treated with either early immunomodulators alone (60 percent) or no early immunotherapy (54 percent). Further, at one-year, no patients in the early anti-TNF-α group had a Pediatric Crohn's Disease Activity Index of greater than 30, compared with 7 percent in the early immunomodulators group and 10 percent in the no early immunotherapy group. Only in the early anti-TNF- α group was normal growth velocity established.


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas D. Walters, Mi–Ok Kim, Lee A. Denson, Anne M. Griffiths, Marla Dubinsky, James Markowitz, Robert Baldassano, Wallace Crandall, Joel Rosh, Marian Pfefferkorn, Anthony Otley, Melvin B. Heyman, Neal LeLeiko, Susan Baker, Stephen L. Guthery, Jonathan Evans, David Ziring, Richard Kellermayer, Michael Stephens, David Mack, Maria Oliva–Hemker, Ashish S. Patel, Barbara Kirschner, Dedrick Moulton, Stanley Cohen, Sandra Kim, Chunyan Liu, Jonah Essers, Subra Kugathasan, Jeffrey S. Hyams. Increased Effectiveness of Early Therapy With Anti–Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease. Gastroenterology, 2014; 146 (2): 383 DOI: 10.1053/j.gastro.2013.10.027

Cite This Page:

American Gastroenterological Association. "Biologic agents provide relief for children newly diagnosed with Crohn's disease." ScienceDaily. ScienceDaily, 3 February 2014. <www.sciencedaily.com/releases/2014/02/140203113557.htm>.
American Gastroenterological Association. (2014, February 3). Biologic agents provide relief for children newly diagnosed with Crohn's disease. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2014/02/140203113557.htm
American Gastroenterological Association. "Biologic agents provide relief for children newly diagnosed with Crohn's disease." ScienceDaily. www.sciencedaily.com/releases/2014/02/140203113557.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins